Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00670228 · ClinicalTrials.gov registry record · Phase 3
Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
NCT00670228 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 34 participants.
The verdict
NCT00670228, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
Study Summary
Primary objective: To demonstrate that in hyperglycemic subjects with anterior STEMI (ST Elevation Myocardial Infarction) undergoing Percutaneous Coronary Intervention (PCI), tight glycemic control using insulin glulisine and insulin glargine, i.e. Intensive Insulin Therapy (IIT), results in reducing infarct size at day 60 versus (vs) Standard Glycemic Care (SGC). Secondary objectives: To demonstrate that tight glycemic control using insulin glulisine and insulin glargine reduces markers of inflammation and improves Left Ventricular (LV) function and Cardio-Vascular (CV) outcomes from baseline values, in hyperglycemic subjects with STEMI undergoing Percutaneous Coronary Intervention (PCI).
Interventions
- DRUG Standard Therapy
- DRUG Insulin Glargine (LANTUS)
- DRUG Insulin Glulisine (Apidra)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00670228
The ClinicalTrials.gov registry entry for NCT00670228 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Standard Therapy is the first listed.
NCT00670228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00670228 about?
NCT00670228 is a clinical study titled "Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction". Primary objective: To demonstrate that in hyperglycemic subjects with anterior STEMI (ST Elevation Myocardial Infarction) undergoing Percutaneous Coronary Intervention (PCI), tight glycemic control using insulin glulisine and insulin glargine, i.e. Intensive Insulin Therapy (IIT), results in reduci...
What is the current status of trial NCT00670228?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2008-04. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00670228?
The interventions under investigation include: Standard Therapy (DRUG), Insulin Glargine (LANTUS) (DRUG), Insulin Glulisine (Apidra) (DRUG).
Who is sponsoring clinical trial NCT00670228?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.